Bio-Connect

anti-ADAM17 (human), mAb (rec.) (blocking) (D1(A12)) (Fab Fragment) (His)

Research Use Only
AG-27B-6003PF
AdipoGen Life Sciences
ApplicationsFunctional Assay, Neutralisation/Blocking
Product group Antibodies
ReactivityHuman
TargetADAM17
Price on request
Packing Size
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    anti-ADAM17 (human), mAb (rec.) (blocking) (D1(A12)) (Fab Fragment) (His)
  • Delivery Days Customer
    10
  • Applications
    Functional Assay, Neutralisation/Blocking
  • Certification
    Research Use Only
  • Clonality
    Monoclonal
  • Clone ID
    D1(A12)
  • Concentration
    1 mg/ml
  • Estimated Purity
    >95%
  • Gene ID6868
  • Target name
    ADAM17
  • Target description
    ADAM metallopeptidase domain 17
  • Target synonyms
    a disintegrin and metalloproteinase 17; ADAM metallopeptidase domain 18; ADAM18; cartilage snake venom-like protease; CD156B; CSVP; disintegrin and metalloproteinase domain-containing protein 17; NISBD; NISBD1; snake venom-like protease; TACE; TNF-alpha convertase; TNF-alpha convertase enzyme; TNF-alpha converting enzyme; tumor necrosis factor, alpha, converting enzyme
  • Host
    Human
  • Scientific Description
    ADAM17 (Disintegrin and metalloproteinase domain-containing protein 17), also called TACE (Tumor necrosis factor-alpha-converting enzyme) is the prototype of the ADAM family of ectodomain shedding proteases (sheddase). ADAM17 is understood to be involved in the processing of TNF-alpha at the surface of the cell and from within the intracellular membranes of the trans-Golgi network. This process involves the cleavage and release of a soluble ectodomain from membrane-bound pro-proteins (such as pro-TNF-alpha) and is of known physiological importance. ADAM17 is responsible for the processing of a diverse variety of membrane-anchored cytokines, cell adhesion molecules, receptors, ligands and enzymes, including cleaving epidermal growth factor receptor (EGFR) ligands and extracellular Notch1. The proteolytic cleavage is an indispensable activation event for many of these substrates, ADAM17 has emerged as an attractive therapeutic target for the treatment of inflammatory diseases (e.g. rheumatoid arthritis) or inflammation associated cancer. - Recombinant Antibody. Recognizes the catalytic and non-catalytic domain of human ADAM17 (TACE) through its variable light (VL) domain and variable heavy (VH) domain, respectively. Does not bind recombinant mouse ADAM17 ectodomain. Species cross-reactivity: Human. Clone: D1(A12). Isotype: Human Fab fragment, kappa, His-tagged. Applications: FUNC, FUNC (Blocking). Host: E. coli. Liquid. In PBS. ADAM17 (Disintegrin and metalloproteinase domain-containing protein 17), also called TACE (Tumor necrosis factor-alpha-converting enzyme) is the prototype of the ADAM family of ectodomain shedding proteases (sheddase). ADAM17 is understood to be involved in the processing of TNF-alpha at the surface of the cell and from within the intracellular membranes of the trans-Golgi network. This process involves the cleavage and release of a soluble ectodomain from membrane-bound pro-proteins (such as pro-TNF-alpha) and is of known physiological importance. ADAM17 is responsible for the processing of a diverse variety of membrane-anchored cytokines, cell adhesion molecules, receptors, ligands and enzymes, including cleaving epidermal growth factor receptor (EGFR) ligands and extracellular Notch1. The proteolytic cleavage is an indispensable activation event for many of these substrates, ADAM17 has emerged as an attractive therapeutic target for the treatment of inflammatory diseases (e.g. rheumatoid arthritis) or inflammation associated cancer.
  • Reactivity
    Human
  • Storage Instruction
    2°C to 8°C,-20°C
  • UNSPSC
    12352203